Could STI testing be the key to getting more women on HIV prevention?

NCT ID NCT06743204

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study in Uganda tests whether adding lab tests for common sexually transmitted infections (STIs) to standard HIV risk screening helps more women start and stick with PrEP, a daily pill that prevents HIV. About 4,500 HIV-negative women aged 15-39 will be randomly assigned to either standard screening or standard screening plus STI testing. Researchers will track PrEP use, adherence, and persistence over six months to see if the extra testing makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
STI diagnostic testing for chlamydia, gonorrhea, trichomonas, and syphilis
What this could lead to
If it works, this could show that routine STI testing helps identify more women at risk for HIV and encourages them to use PrEP consistently, potentially reducing new HIV infections in Africa.
What could go wrong
This is a large trial, but it's testing a screening strategy, not a new drug. The benefit depends on whether women act on the test results, and results may not apply outside Uganda.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHLAMYDIA FEMALES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rakai Health Sciences Program

    RECRUITING

    Kalisizo, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.